Chardan Capital Maintains Buy on Adverum Biotechnologies, Adjusts Price Target To $40 ((reverse stock split 1:10))
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has maintained its Buy rating on Adverum Biotechnologies (NASDAQ:ADVM) and adjusted the price target to $40 from $4, following a reverse stock split of 1:10.
July 18, 2024 | 9:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating on Adverum Biotechnologies and adjusted the price target to $40 from $4, reflecting a 1:10 reverse stock split.
The reiteration of a Buy rating and a significant adjustment in the price target by Chardan Capital is a positive signal for investors. The reverse stock split consolidates shares, potentially making the stock more attractive to institutional investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100